NICE chief: Approval changes 'won't increase NHS drugs bill'

Sir Andrew Dillon

The head of the National Institute of Health and Care Excellence has suggested the NHS will not pay more overall for branded pharmaceuticals in future as a result of proposed changes to the way the organisation assesses the value of new drugs.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here